-
1.发明授权Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto 有权浓缩因子VIII：含有冯维勒布兰德因子及其相关过程公开(公告)号：US07625866B2
公开(公告)日：2009-12-01
申请号：US10670563
申请日：2003-09-26
IPC分类号： A61K38/37
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a concentrate and a process for producing a factor VIII:C-containing von Willebrand factor by fractional precipitation from a liquid comprising factor VIII:C and von Willebrand factor, resulting in an increased content of high molecular weight multimers of von Willebrand factor and a ratio of the vWF:RCoF activity to vWF:Ag of greater than 1.
摘要翻译： 本发明涉及一种浓缩物和通过从包含因子VIII：C和von Willebrand因子的液体中分级沉淀来生成因子VIII：含C的血管性血友病因子的方法，导致von Willebrand的高分子量多聚体的含量增加 因子和vWF：RCoF活性与vWF的比例：Ag大于1。
-
2.发明授权Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X 失效凝血因子II，VII，IX和X的血浆或浓缩物的巴氏消毒过程公开(公告)号：US06346277B1
公开(公告)日：2002-02-12
申请号：US08415166
申请日：1995-03-31
IPC分类号： A61K3516
CPC分类号： A61L2/0023 , A61K35/14 , A61K38/48 , A61L2/04 , Y10S514/802
摘要： The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calcium ions and a chelating agent and, optionally, an amino acid, a saccharide or sugar alcohol, antithrombin III and/or heparin. The product can be used for the treatment of blood coagulation disorders.
摘要翻译： 本发明涉及一种制备实质上不含病毒的凝血因子II，VII，IX和X的产物的方法，该方法包括在钙离子和螯合剂存在下加热含有这些因子的含水液体 试剂和任选的氨基酸，糖或糖醇，抗凝血酶III和/或肝素。 该产品可用于治疗凝血障碍。
-
公开(公告)号：US20090298760A1
公开(公告)日：2009-12-03
申请号：US12223616
申请日：2007-02-03
申请人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
发明人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
CPC分类号： A61K38/4846 , A61K9/0019 , A61K38/00 , A61K38/385 , C07K14/76 , C07K2319/00 , C07K2319/31 , C12N9/6437 , C12N9/96 , C12N15/62 , C12Y304/21021
摘要： The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
摘要翻译： 本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。 更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码干扰肽接头，这种编码的衍生物表现出改进的稳定性和延长的功能 血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物 制备这些重组蛋白及其衍生物。 本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。
-
公开(公告)号：US20100222554A1
公开(公告)日：2010-09-02
申请号：US12226188
申请日：2007-04-02
IPC分类号： C07K1/107
CPC分类号： C12N9/644 , A61K47/62 , A61K47/643 , C07K2319/31 , C12N9/14 , C12N9/6424 , C12N9/6437
摘要： The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. I.e., the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide.
摘要翻译： 本发明涉及与其未修饰的亲本多肽相比具有增加的体内恢复的修饰的治疗性多肽的领域。 即，本发明涉及治疗性多肽与通过连接肽直接或任选连接的恢复增强多肽的融合。
-
公开(公告)号：US08765915B2
公开(公告)日：2014-07-01
申请号：US12223616
申请日：2007-02-03
申请人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
发明人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
IPC分类号： A61K38/35 , A61K38/38 , C07K14/745 , C07K14/76 , C07K14/765 , C12N9/64 , A61K38/00
CPC分类号： A61K38/4846 , A61K9/0019 , A61K38/00 , A61K38/385 , C07K14/76 , C07K2319/00 , C07K2319/31 , C12N9/6437 , C12N9/96 , C12N15/62 , C12Y304/21021
摘要： The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
摘要翻译： 本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。 更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码干扰肽接头，这种编码的衍生物表现出改进的稳定性和延长的功能 血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物 制备这些重组蛋白及其衍生物。 本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)
